David B. Zhen, MD, discusses the results of the phase 3 CheckMate 649 trial in patients with advanced gastric cancer, ...
A 19-year-old is celebrating being cancer-free – a year after he was told that there was no hope and to “go home and make ...
The majority are in the very early preclinical stage of development, but applications for regulatory approval have been ...
Panelists discuss the FDA approval of subcutaneous nivolumab based on the CheckMate-67T trial findings, highlighting its ...
The FDA recently approved Vertex Pharmaceuticals Incorporated’s Journavx (suzetrigine), a first-in-class non-opioid medication for treating moderate to severe acute pain in adults. Journavx, approved ...
The 12-month open-label extension of the PACIFIC trial demonstrated that bexicaserin significantly reduced seizure frequency ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback